Document Detail

Pharmacologic prevention of anthracycline-induced cardiomyopathy.
MedLine Citation:
PMID:  19690476     Owner:  NLM     Status:  MEDLINE    
Anthracyclines are highly effective anticancer drugs. However, a major factor limiting their use in humans is a cumulative, dose-related cardiotoxicity which can result in a permanent loss of cardiomyocytes, which ultimately leads to asymptomatic and symptomatic heart failure. Experiences with various approaches to reduce the cardiotoxicity of anthracyclines without jeopardizing their antineoplastic effects have been reported in the oncology literature. This article reviews the etiology and natural history of anthracycline-induced cardiotoxicity and provides options available for limiting and/or preventing cardiotoxicity.
Kuldeep Maradia; Maya Guglin
Related Documents :
8069596 - Niosome encapsulated of vincristine sulfate: improved anticancer activity with reduced ...
19706756 - Classification of chemotherapeutic agents based on their differential in vitro effects ...
21996056 - Ph-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates.
11470606 - Microtubule-stabilizing agents: a growing class of important anticancer drugs.
23770226 - Mathematical modeling of drug release from nanostructured porous si: combining carrier ...
24252806 - Effect of coumarin derivative-mediated inhibition of p-glycoprotein on oral bioavailabi...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiology in review     Volume:  17     ISSN:  1538-4683     ISO Abbreviation:  Cardiol Rev     Publication Date:    2009 Sep-Oct
Date Detail:
Created Date:  2009-08-19     Completed Date:  2009-10-26     Revised Date:  2010-01-07    
Medline Journal Info:
Nlm Unique ID:  9304686     Medline TA:  Cardiol Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  243-52     Citation Subset:  IM    
Department of Cardiology, University of South Florida, Tampa, FL 33618, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Anthracyclines / adverse effects*
Antineoplastic Agents / adverse effects*
Cardiomyopathies / chemically induced*,  prevention & control*
Dose-Response Relationship, Drug
Iron Chelating Agents / therapeutic use
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Anthracyclines; 0/Antineoplastic Agents; 0/Iron Chelating Agents
Erratum In:
Cardiol Rev. 2009 Nov-Dec;17(6):299

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Should saphenous vein grafts be the conduits of last resort for coronary artery bypass surgery?
Next Document:  Identification of the methylator (serrated) colorectal cancer phenotype through precursor serrated p...